I. Cuesta Esteve

I. Cuesta Esteve

Auto-generated profile, based on publicly available information

I. Cuesta Esteve

Presidente de la Asociación Española de Vacunología

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Journal of Language Contact
Verified
Journal Article
Open access
PDF file
IEIsabelle Estève
Isabelle Estève
AMAgnès Millet
Agnès Millet
Cette contribution propose des outils de transcription et d'analyse des pratiques langagières de locuteurs sourds, dont les discours sont inscrits le plus souvent dans le bilinguisme, le contact de langues et la bimodalité. Réalisée sous le logiciel ELAN®, la grille hiérarchique que nous proposons et dont nous détaillons tous les niveaux d'analyse autorise des approches qualitatives et quantifiées des observables. Elle permet de rendre compte de la diversité des moyens utilisés (verbal/non verbal ; vocal/gestuel), de leur combinatoire et de leurs interactions. Elle permet également d'envisager des indices de complexité syntaxique et discursive, qui se construisent dans cette bilingualité particulière ancrée d'entrée de jeu dans la bimodalité. Les visées sont théoriques et descriptives et doivent trouver des prolongements psycholinguistiques et didactiques.

3 April 2020 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
NZNéboa Zozaya
Néboa Zozaya
BRB. Alcalá Revilla
B. Alcalá Revilla
PMP. Arrazola Martínez
P. Arrazola Martínez
JBJ. R. Chávarri Bravo
J. R. Chávarri Bravo
IEI. Cuesta Esteve
I. Cuesta Esteve
AHA. Hidalgo-Vega
A. Hidalgo-Vega
Objective: To advance the development of an ideal and sustainable framework agreement for the public procurement of vaccines in Spain, and to agree on the desirable award criteria and their relative weight. Methods: A multidisciplinary committee of seven health-care professionals and managers developed a partial multi-criteria decision analysis to determine the award criteria that should be considered and their specific weights for the public procurement of routine vaccines and seasonal influenza vaccines, considering their legal viability. A re-test of the results was carried out. The current situation was analyzed through 118 tender specifications and compared to the ideal framework. Results: Price is the prevailing award criterion for the public procurement of both routine (weighting of 60% versus 40% for all other criteria) and influenza (36% versus 64%) vaccines. Ideally, 22 criteria should be considered for routine vaccines, grouped and weighted into five domains: efficacy (weighting of 29%), economic aspects (27%), vaccine characteristics (22%), presentation form and packaging (13%), and others (9%). Per criteria set, price was the most important criterion (22%), followed by effectiveness (9%), and composition/formulation (7%). Regarding influenza vaccines, 20 criteria were selected, grouped, and weighted: efficacy (29%), economic aspects (25%), vaccine characteristics (20%), presentation form and packaging (16%), and others (11%). Per criteria set, price was also the most relevant criterion (19%), followed by composition/formulation (8%), and effectiveness (8%). Conclusions: Contrary to the current approach, technical award criteria should prevail over economic criteria in an ideal and sustainable framework agreement for the public procurement of vaccines.